Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Bakthavatsalam, Subha, Mark L. Sleeper, Azim Dharani, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.” Angew Chem Int Ed Engl 57, no. 39 (September 24, 2018): 12780–84. https://doi.org/10.1002/anie.201807582.

PMID
30025197
Full Text

Powles, Thomas, Robert J. Motzer, Bernard Escudier, Sumanta Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, et al. “Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.” Br J Cancer 119, no. 6 (September 2018): 663–69. https://doi.org/10.1038/s41416-018-0164-0.

PMID
30197417
Full Text

Freedman, Jennifer A., Yanru Wang, Xuechan Li, Hongliang Liu, Patricia G. Moorman, Daniel J. George, Norman H. Lee, Terry Hyslop, Qingyi Wei, and Steven R. Patierno. “Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.” Carcinogenesis 39, no. 7 (July 3, 2018): 879–88. https://doi.org/10.1093/carcin/bgy062.

PMID
29726910
Full Text

LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.” In Cancer Epidemiology Biomarkers & Prevention, 27:46–46. AMER ASSOC CANCER RESEARCH, 2018.

Scholars@Duke

LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells.” In Cancer Epidemiology Biomarkers & Prevention, 27:148–148. AMER ASSOC CANCER RESEARCH, 2018.

Scholars@Duke

George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.

Scholars@Duke

Labriola, Matthew, Wen-Chi Foo, Daniel J. George, and Tian Zhang. “Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.” Clin Genitourin Cancer 16, no. 3 (June 2018): e509–12. https://doi.org/10.1016/j.clgc.2018.02.017.

PMID
29636282
Full Text

Batich, Kristen A., Janet S. Staats, Cliburn Chan, Cecile Krejsa, Daniel J. George, Kent J. Weinhold, and Tian Zhang. “Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 36:e16519–e16519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e16519.

Full Text

Slovin, Susan, William Clark, Joan Carles, Andrew Krivoshik, Jung Wook Park, Fong Wang, and Daniel George. “Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.” Jama Oncol 4, no. 5 (May 1, 2018): 702–6. https://doi.org/10.1001/jamaoncol.2017.3361.

PMID
29222530
Full Text

Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.” Eur J Cancer 94 (May 2018): 115–25. https://doi.org/10.1016/j.ejca.2018.02.012.

PMID
29550566
Full Text

Pages